Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amitinib
- Development stage
- Phase 2
- Lead developer
- Affiliated Cancer Hospital of Nanjing Medical University
- Modality
- Small Molecules
- Administration
- Oral, Enteral, Rectal
01
Overview
Amitinib is a pharmaceutical agent developed for the treatment of advanced non-small cell lung cancer (NSCLC) in patients with epidermal growth factor receptor (EGFR) mutations. Clinical studies have indicated that amitinib offers comparable short-term efficacy and safety to first-line ositinib, while also demonstrating an improvement in patients' quality of life and a lower medical cost. Its mechanism of action is understood to involve targeting the specific EGFR mutations prevalent in this type of cancer.
- Brand names
- Ameile
- Other names
- Ametinib
02
Targets
Beyond the preview
Go deeper on amitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amitinib.